Publicaciones en colaboración con investigadoras/es de Memorial Sloan Kettering Cancer Center (39)

2023

  1. Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCL

    Blood, Vol. 141, Núm. 18, pp. 2194-2205

2022

  1. Immobilization of Biantennary N-Glycans Leads to Branch Specific Epitope Recognition by LSECtin

    ACS Central Science, Vol. 8, Núm. 10, pp. 1415-1423

  2. The Oncogenic PI3K-Induced Transcriptomic Landscape Reveals Key Functions in Splicing and Gene Expression Regulation

    Cancer Research, Vol. 82, Núm. 12, pp. 2269-2280

2021

  1. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

  2. TRK XDFG mutations trigger a sensitivity switch from type i to ii kinase inhibitors

    Cancer Discovery, Vol. 11, Núm. 1, pp. 126-141

2020

  1. Author Correction: Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate (Nature Genetics, (2009), 41, 5, (619-624), 10.1038/ng.370)

    Nature Genetics

  2. Epigenetic reprogramming sensitizes immunologically silent EBV1 lymphomas to virus-directed immunotherapy

    Blood, Vol. 135, Núm. 21, pp. 1870-1881

  3. FOXA1 Mutations Reveal Distinct Chromatin Profiles and Influence Therapeutic Response in Breast Cancer

    Cancer Cell, Vol. 38, Núm. 4, pp. 534-550.e9

2019

  1. Corrupted coordination of epigenetic modifications leads to diverging chromatin states and transcriptional heterogeneity in CLL

    Nature Communications, Vol. 10, Núm. 1

  2. Epigenetic evolution and lineage histories of chronic lymphocytic leukaemia

    Nature, Vol. 569, Núm. 7757, pp. 576-580

  3. PI3K Inhibition Activates SGK1 via a Feedback Loop to Promote Chromatin-Based Regulation of ER-Dependent Gene Expression

    Cell Reports, Vol. 27, Núm. 1, pp. 294-306.e5

  4. Somatic mutations and cell identity linked by Genotyping of Transcriptomes

    Nature, Vol. 571, Núm. 7765, pp. 355-360

2017

  1. Epigenetic identity in AML depends on disruption of nonpromoter regulatory elements and is affected by antagonistic effects of mutations in epigenetic modifiers

    Cancer Discovery, Vol. 7, Núm. 8, pp. 868-883

  2. Inhibition of Polo-like kinase 1 during the DNA damage response is mediated through loss of Aurora A recruitment by Bora

    Oncogene, Vol. 36, Núm. 13, pp. 1840-1848

  3. MTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer

    Nature, Vol. 547, Núm. 7661, pp. 109-113

2016

  1. Optimized Protocol to Analyze Changes in the Lipidome of Xenografts after Treatment with 2-Hydroxyoleic Acid

    Analytical Chemistry, Vol. 88, Núm. 1, pp. 1022-1029

  2. Stratification and therapeutic potential of PML in metastatic breast cancer

    Nature Communications, Vol. 7

  3. The metabolic co-regulator PGC1α suppresses prostate cancer metastasis

    Nature Cell Biology, Vol. 18, Núm. 6, pp. 645-656

2015

  1. Methodological aspects of the molecular and histological study of prostate cancer: Focus on PTEN

    Methods, Vol. 77, pp. 25-30

  2. Regulation of ceramide generation during macrophage apoptosis by ASMase and de novo synthesis

    Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids, Vol. 1851, Núm. 11, pp. 1482-1489